Royalty Pharma is a US-based company that buys biopharmaceutical royalties and funds innovation in the biopharmaceutical industry. It collaborates with academic institutions, research hospitals, biotech firms, and pharmaceutical companies to identify and acquire royalties on various biopharmaceutical therapies. Its portfolio consists of royalties on about 35 marketed therapies and 10 development-stage product candidates addressing several therapeutic areas, including rare disease, neurology, cancer, hematology, infectious disease, and diabetes.